Last updated on February 2020

Short Course Daratumumab in Patients With Multiple Myeloma


Brief description of study

The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination with lenalidomide has on people and their risk of multiple myeloma. The study is also designed to test the amount of remaining myeloma cells in your body after treatment with daratumumab which is known as minimal residual disease (MRD).

Clinical Study Identifier: NCT03490344

Find a site near you

Start Over